_parp-inhibitor-monotherapy.jpg "PARP inhibitor monotherapy from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 5 sec
✓ Published: 26-May-2023
✓ Published: 26-May-2023
Description:
In this GU CONNECT programme, brought to you by Dr Neal Shore, you’ll follow a patient through their metastatic castration-resistant prostate cancer (mCRPC) journey and explore the clinical implementation of genetic testing and monotherapy treatment with a PARPi.nnWatch the 5-minute animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testing and how to use it to assess HRRm status and
In this GU CONNECT programme, brought to you by Dr Neal Shore, you’ll follow a patient through their metastatic castration-resistant prostate cancer (mCRPC) journey and explore the clinical implementation of genetic testing and monotherapy treatment with a PARPi.nnWatch the 5-minute animated video and download the accompanying slides for an update on:nn- Efficacy and safety profiles of PARP inhibitors for prostate cancern- The role of genetic testing and how to use it to assess HRRm status and
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
_negative-charge-and-poly-adp-ribosylation-a-scientific-animation.webp "A short 2D animation describing how a molecule, PARP-1, binds to DNA during the DNA repair process.")
_wicked-fart.webp "Muesli maketh the man.")
_parp-serwis.webp "CreditsnCLIENT: PARPnAGENCY: Scholz & FriendsnPRODUCTION: Dorota SieradzkanANIMATION DIRECTOR: Michal Socha, BrosFXnCREATION: Agnieszka Niska- Wojcik, BrosFXnREALIZATION: BrosFX: Directing, Concept Design, Animation, Postproduction")
_e4-sting-2007.webp "My submission to the E4 stings competition 2007.")
_esmo-e-learning-parp-inhibitors-past-present-and-future.webp "ESMO E-Learning: PARP Inhibitors: Past, Present and Future from parp")
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.webp "β-Nicotinamide Mononucleotide (1094-61-7) Manufacturer - Coftteknnhttps://www.cofttek.com/product/1094-61-7/nnβ-Nicotinamide Mononucleotide (NMN) SpecificationsnnnnName:nβ-Nicotinamide Mononucleotide (NMN)nnnCAS:n1094-61-7nnnPurityn98%nnnMolecular Formula:nC11H15N2O8PnnnMolecular Weight:n334.2208 g/molnnnMelt Point:n96°CnnnChemical name:n((2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphatennnSynonyms:nNicotinamide Mononucleotide; NMN;")
_how-do-genetic-mutations-impact-prostate-cancer-treatment-options.webp "How do genetic mutations impact prostate cancer treatment options? Dr. Himisha Beltran shares how information about genetic mutations play into treatment decisions and discusses the role of PARP inhibitor therapies and immunotherapies.nnDr. Himisha Beltran is Director of Translational Research in the Department of Medical Oncology at Dana-Farber Cancer Institute. Learn more about Dr. Beltran, here: https://www.dana-farber.org/find-a-doctor/himisha-beltran/.")
_technics-su-9070-test.webp "parp")
_negative-charge-and-poly-adp-ribosylation-a-scientific-animation.jpg)
_wicked-fart.jpg)
_parp-serwis.jpg)
_e4-sting-2007.jpg)
_esmo-e-learning-parp-inhibitors-past-present-and-future.jpg)
_-nicotinamide-mononucleotide-1094-61-7-manufacturer-cofttek.jpg)
_how-do-genetic-mutations-impact-prostate-cancer-treatment-options.jpg)
_technics-su-9070-test.jpg)
![[+]](/images/menu.gif){kind=small}